Definitive Notice of the End Result

of the public tender offer by

Samsung Peptide AG, Zug, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

PolyPeptide Group AG, Baar, Switzerland

1. The Offer

On August 31, 2026, Samsung Peptide AG (**Offeror** or **Samsung Peptide**) published the offer prospectus (**Offer Prospectus**) for its public tender offer according to articles 125 et seq. FMIA (**Offer**) for all publicly held registered shares of PolyPeptide Group AG (**PolyPeptide** or **Company**) with a nominal value of CHF 0.01 each (each a **PolyPeptide Share**, all together **PolyPeptide Shares**). The offer price for each PolyPeptide Share is CHF 44.31 net in cash (**Offer Price**) (as further described in the Offer Prospectus).

The Offer relates to a maximum of 33,016,411 PolyPeptide Shares, as further detailed in section B.2 (*Object of the Offer*) of the Offer Prospectus.

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

2. End Result

As of the end of the Additional Acceptance Period on October 30, 2026, 4:00 p.m. Swiss time, the participation of the Offeror and the persons acting in concert with the Offeror amounts to 32,458,892 PolyPeptide Shares in aggregate, corresponding to 97.99% of the issued share capital and voting rights of PolyPeptide (*participation rate*). 32,350,302 PolyPeptide Shares were tendered into the Offer until the end of the Additional Acceptance Period, corresponding to 97.98% of all PolyPeptide Shares to which the Offer relates (*success rate*). The Offeror and the persons acting in concert with the Offeror (excluding PolyPeptide and its direct and indirect Subsidiaries as well as the Principal Shareholder and all companies directly or indirectly controlled by the Principal Shareholder) have, between July 20, 2026 and the end of the Additional Acceptance Period, acquired a total of 17 PolyPeptide Shares on- or off-exchange, which have been tendered into the offer.

The following overview summarizes the end result:

	Number of PolyPeptide Shares	In % of voting rights/share capital (*participation rate*)	In % of PolyPeptide Shares to which the Offer relates (*success rate*)
PolyPeptide Shares tendered into the Offer	32,350,302	97.66%	97.98%
PolyPeptide Shares held by the Offeror and the persons acting in concert with the Offeror at the end of the Additional Acceptance Period	108,590	0.33%	
End Result	32,458,892	97.99%	

3. Satisfaction of Offer Conditions

After expiry of the Additional Acceptance Period, the Offer Conditions pursuant to section B.7.1(a) (*Minimum Acceptance Rate*), section B.7.1(d) (*No Material Adverse Effect*) and section B.7.1(g) (*Resignation and Election of Members of the Board of Directors/Mandate Agreements*) of the Offer Prospectus have been satisfied.

The Offeror declared the Offer successful (*zustande gekommen*), subject to the other Offer Conditions pursuant to section B.7.1 of the Offer Prospectus.

4. Settlement / Postponement

The Settlement of the Offer, subject to satisfaction of the Offer Conditions pursuant to section B.7.1 of the Offer Prospectus, i.e. section B.7.1(b) (*Merger and FDI Clearances*), section B.7.1(c) (*No Injunction*), section B.7.1(e) (*Removal of Transfer Restrictions and Voting Limitations from PolyPeptide's Articles of Association*), section B.7.1(f) (*Registration in the Share Register of PolyPeptide*), section B.7.1(h) (*No Adverse Resolutions by the Shareholders' Meeting of PolyPeptide*) and section B.7.1(i) (*No Acquisition or Divestment of Material Assets or Incurrence or Repayment of Material Indebtedness*) of the Offer Prospectus has been postponed in accordance with section B.7.3 (*Period for which the Offer Conditions are in Force and Effect and Deferral*) of the Offer Prospectus. Based on the current understanding of the regulatory approval procedures in various countries (see the Offer Condition pursuant to section B.7.1(b) (*Merger and FDI Clearances*) of the Offer Prospectus), it is expected that the transaction will be completed towards the end of 2026 or in Q1 2027.

Upon fulfilment of all Offer Conditions of the Offer pursuant to section B.7.1 (*Offer Conditions*) of the Offer Prospectus, the Offeror will announce the Settlement date.

5. Squeeze-out and Delisting

After the Settlement, as set out in section E.4 (*Intentions of the Offeror with Respect to PolyPeptide*) of the Offer Prospectus, the Offeror intends to request the cancellation of the outstanding publicly held PolyPeptide Shares, or to merge PolyPeptide with the Offeror or a Swiss company directly or indirectly controlled by the Offeror, whereby the remaining public shareholders of PolyPeptide will receive a cash compensation, but no shares of the surviving company, if permitted by law. Furthermore, after the Settlement the Offeror intends, in compliance with the legal requirements applying to PolyPeptide, to have PolyPeptide apply to SIX Exchange Regulation for the delisting of the PolyPeptide Shares in accordance with the Listing Rules and for an exemption from certain disclosure and publicity obligations under the Listing Rules until the date of delisting of the PolyPeptide Shares (see also section J.6 (*Cancellation, Squeeze-out Merger and Delisting*) of the Offer Prospectus).

6. Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus is available at the designated offer website of the Offeror (https://samsungbiologics.com/offer) and may also be obtained free of charge in German, French and English from UBS AG, Investment Bank, Swiss Prospectus Switzerland, P.O. Box, CH-8098 Zurich, Switzerland (email: swiss-prospectus@ubs.com; telephone: +41 44 239 47 03).

	Swiss securities number	ISIN	Ticker symbol
PolyPeptide Shares not tendered (first trading line)	111 076 085	CH1110760852	PPGN
PolyPeptide Shares tendered (second trading line)	159 344 976	CH1593449767	PPGNE

Zug, November 5, 2026

Offer Manager: UBS AG, 8001 Zurich, Switzerland